Skip to main content
CGEM
NASDAQ Life Sciences

Cullinan's CLN-978 Phase 1 Data Shows Robust B-Cell Depletion, Favorable Safety

Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$14.87
Mkt Cap
$913.881M
52W Low
$5.68
52W High
$16.74
52W Position info
162% above low
Off High info
11% below high
Rel. Volume info
2.2× avg
Market data snapshot near publication time

CGEM has more than doubled off its 52-week low of $5.68 on elevated volume (2.2× avg).

Summary

Cullinan Therapeutics announced positive initial Phase 1 OUTRACE data for its drug candidate CLN-978, demonstrating robust B-cell depletion and a favorable safety profile in patients with treatment-refractory rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The data, which will be presented at EULAR, showed that 9 of 11 patients achieved over 75% peripheral B-cell depletion at 10 mcg, with early clinical signals of improvement in both RA and SLE patients. This positive early-stage clinical data is a significant de-risking event for a biotech company, indicating potential efficacy and tolerability for a key pipeline asset. Investors will be watching for updated data presentations in June 2026 and the progression of CLN-978 into later-stage clinical trials.

At the time of this announcement, CGEM was trading at $14.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $913.9M. The 52-week trading range was $5.68 to $16.74. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

CGEM - Latest Insights

CGEM
Oct 19, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $13.35
Real-time Price: $11.51 info
Change: -$1.84 (-14%) info
Market Cap: $727.852M info
CGEM
Oct 01, 2026, 7:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.55
Real-time Price: $11.51 info
Change: -$3.04 (-21%) info
Market Cap: $727.852M info
CGEM
Sep 24, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $16.88
Real-time Price: $11.51 info
Change: -$5.37 (-32%) info
Market Cap: $727.852M info
CGEM
Sep 14, 2026, 7:29 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $20.60
Real-time Price: $11.51 info
Change: -$9.09 (-44%) info
Market Cap: $727.852M info
CGEM
Sep 13, 2026, 7:15 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $21.11
Real-time Price: $11.51 info
Change: -$9.60 (-45%) info
Market Cap: $727.852M info